Poseida Ebitda from 2010 to 2024

PSTX Stock  USD 9.33  0.05  0.53%   
Poseida Therapeutics EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -114.5 M in 2024. During the period from 2010 to 2024, Poseida Therapeutics EBITDA regression line of annual values had significance of  0.0004 and arithmetic mean of (54,911,727). View All Fundamentals
 
EBITDA  
First Reported
2019-03-31
Previous Quarter
-27.8 M
Current Value
23.9 M
Quarterly Volatility
26.6 M
 
Covid
Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.1 M, Income Tax Expense of 112.3 K or Tax Provision of 112.3 K, as well as many indicators such as Price To Sales Ratio of 4.45, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Poseida Therapeutics Correlation against competitors.
For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

Latest Poseida Therapeutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of Poseida Therapeutics over the last few years. It is Poseida Therapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Poseida Ebitda Regression Statistics

Arithmetic Mean(54,911,727)
Coefficient Of Variation(82.05)
Mean Deviation38,215,236
Median(20,880,000)
Standard Deviation45,055,783
Sample Variance2030T
Range124.6M
R-Value(0.79)
Mean Square Error807.1T
R-Squared0.63
Significance0.0004
Slope(8,001,705)
Total Sum of Squares28420.3T

Poseida Ebitda History

2024-114.5 M
2023-109 M
2022-54.8 M
2021-117.1 M
2020-145.5 M
2019-75.1 M
2018-40.7 M

About Poseida Therapeutics Financial Statements

Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-109 M-114.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.